Note: This post was originally published on Mayo Clinic's Advancing the Science blog on April 30, 2013
Edward Loftus Jr., M.D., a gastroenterologist at Mayo Clinic specializing in the care and evaluation of patients with IBD, discusses the implications of recent article published in Alimentary Pharmacology & Therapeutics that found a group of patients with IBS to have higher CDAI scores than patients with Crohn’s disease.
Specifically, Dr. Loftus mentions:
- Because signs of Crohn’s disease are neither sensitive nor specific, clinicians can’t rely on symptoms alone to make treatment decisions.
- It is important to support the CDAI score with endoscopic measures, CRP levels, or measure of inflammation in the stool.
For more information on IBD, visit: mayoclinic.org/IBD